Recordati Rare Diseases  
ATTN: Marilyn Brandt, PhD, RAC  
Director, Regulatory Affairs  
100 Corporate Drive  
Lebanon, NJ 08833  

Dear Dr. Brandt:

Please refer to your Supplemental New Drug Application (sNDA) dated submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for NeoProfen (ibuprofen lysine) Injection, 10 mg/mL  

This “Prior Approval” supplemental new drug application provides for labeling revised as follows:

1. The HIGHLIGHTS/RECENT MAJOR CHANGES section has been revised by removing old information and adding a reference to the changes in the Dosage and Administration section noted in the current supplement.

2. Cross-references have been added throughout the HIGHLIGHTS section.

3. The HIGHLIGHTS/DOSAGE AND ADMINISTRATION section has been revised and now reads as follows:

   DOSAGE AND ADMINISTRATION
   • A course of therapy is three doses administered I.V. (2.1)
   • An initial dose of 10 mg/kg (based on birth weight) is followed by two doses of 5 mg/kg each, after 24 and 48 hours (2.1)
   • Do not administer if anuria or marked oliguria (<0.6 mL/kg/hr) is evident at the scheduled time of the second or third dose (2.1)

4. Contact information provided in HIGHLIGHTS/ADVERSE REACTIONS has been revised as Recordati Rare Diseases is now the application owner.

5. The following information has been added to section 2.2 (DOSAGE AND ADMINISTRATION/Directions for Use):

   Do not use NeoProfen if particulate matter is observed.
After the first withdrawal from the vial, any solution remaining must be discarded because NeoProfen contains no preservative.

6. Recordati Rare Diseases is now shown as the owner of the application.

7. The revision date has been updated.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Reference ID: 3416386
You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Russell Fortney, Regulatory Project Manager, at (301) 796-1068.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling